Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome and environmental influences should be considered in the study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment outcomes and could contribute to a more personalized approach to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Active cholesterol metabolites are produced by interspecies biosynthetic pathways. Bile acids are the main metabolites of cholesterol (CHOL). Primary bile acids (blue ovals; cholic acid (CA) and chenodeoxycholic acid (CDCA)) are produced by endogenous enzymes in the liver and are modified by bacteria of the genus Clostridia colonizing the gut to form secondary bile acids (yellow ovals; lithocholic acid (LCA) and deoxycholic acid [18]). Arrows broken by double lines represent multiple enzymatic steps and only the genes encoding the rate limiting enzymes are listed. The bacterial operon baiABCDEFGHI encodes eight enzymes and a bile acid transporter that together form the pathway for synthesis of secondary bile acids. The amino acids glycine and taurine are conjugated to primary and secondary bile acids in the liver by the host encoded bile acid-CoA amino acid transferase (BAAT) to form tauro- and glycolithocholic acid (TLCA, GLCA) and tauro- and glycodeoxycholic acid (TDCA GDCA). Gut bacteria of genus Lactobacillus catalyze the conversion of cholesterol metabolites to coprostanol (COPR) and can limit the intestinal absorption of cholesterol.](https://figures.cochat.ai/paper-figures/9948cbeee5e94e979366d6651fafcaf5/enteric-microbiome-metabolites-correlate-with-response-to-simvastatin-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, the response to simvastatin treatment (indicated by LDL cholesterol levels) is positively associated with the pretreatment levels of three microbiota-produced secondary bile acids: lithocholic acid, taurolithocholic acid and glycolithocholic acid.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 4×
“recently have implicated enteric bacteria and phosphatidylcholine metabolism in the pathogenesis of cardiovascular disease [15].”
BackgroundInfluentialRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829 · cited 1×
“have suggested that probiotics, by altering intestinal microflora, can alter the enterohepatic circulation of secondary bile acids [36].”
BackgroundMetabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
BackgroundSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“The SLCO1B1 transporter is of particular interest because it is known to transport simvastatin from plasma into the liver, and SNP rs4149056 has been associated with statin-induced myopathy in individuals treated with high dose simvastatin [34].”
BackgroundXenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807 · cited 2×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundClayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., & Nicholson, J. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904489106 · Cited by 765 · cited 4×
“It is becoming increasingly clear that gut microbial symbiots are critical for normal digestion and defense, and also play an important role in development of disease [15] and in metabolizing orally ingested therapeutics [12].”
BackgroundInfluentialGut microbiome-host interactions in health and disease
Kinross, J. M., Darzi, A. W., & Nicholson, J. K. (2011) · Genome Medicine · doi:10.1186/gm228 · Cited by 691 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
BackgroundMetabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670 · cited 2×
“A new field is evolving called Pharmacometabolomics (also pharmacometabonomics) for applications of metabolomics in personalized medicine [10] and where biochemical data is being used to inform about treatment outcomes.”
BackgroundSelf-citationA Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641 · cited 1×
“These transporters are also responsible for the transport of bile acids in the gastrointestinal tract and liver [28,29].”
BackgroundEndocrine functions of bile acids
Houten, S. M., Watanabe, M., & Auwerx, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601049 · Cited by 580 · cited 2×
“Primary bile acids (blue ovals; cholic acid (CA) and chenodeoxycholic acid (CDCA)) are produced by endogenous enzymes in the liver and are modified by bacteria of the genus Clostridia colonizing the gut to form secondary bile acids (yellow ovals; lithocholic acid (LCA) and deoxycholic acid [18]).”
BackgroundShitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576 · cited 1×
“Primary bile acids (CA and CDCA) and simvastatin are all metabolized by the P450 enzyme CYP3A4 [21,22].”
BackgroundSystems genetics of complex traits in Drosophila melanogaster
Ayroles, J. F., Carbone, M. A., Stone, E. A., Jordan, K. W., Lyman, R. F., Magwire, M. M., Rollmann, S. M., Duncan, L. H., Lawrence, F., Anholt, R. R. H., et al. (2009) · Nature Genetics · doi:10.1038/ng.332 · Cited by 499 · cited 1×
“We tested the correlation of pretreatment metabolites with drug response. Metabolites were log-transformed before correlation testing. For FR subjects, Spearman's correlation coefficient was used to obtain correlation coefficients between the pretreatment level of each metabolite with changes in LDL-C or HDL-C. Becaus…”
MethodSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470 · cited 1×
“Polymorphisms in these proteins are known to influence simvastatin pharmacokinetics [25,26,27].”
BackgroundSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Removal of Cholesterol by Lactobacilli via Incorporation and Conversion to Coprostanol
Lye, H.-S., Rusul, G., & Liong, M.-T. (2010) · Journal of Dairy Science · doi:10.3168/jds.2009-2574 · Cited by 338 · cited 1×
“Specific strains of Lactobacillae bacteria isolated from fermented dairy products have been characterized by their ability to convert cholesterol to coprostanol and have been suggested as probiotic alternatives for reducing cholesterol levels [20].”
BackgroundMetabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R., & Krishnan, K. R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 293 · cited 1×
“Metabolomics brings powerful tools for mapping the metabolic state of individuals prior to treatment and global biochemical changes induced by drug treatment [7,8,9,10].”
BackgroundSelf-citationMetabonomics in pharmaceutical R & D
Lindon, J. C., Holmes, E., & Nicholson, J. K. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05673.x · Cited by 262 · cited 1×
“There is increasing recognition that intestinal bacteria can metabolize drugs and alter an individual’s response to drug treatment depending on specific bacterial strains present [35].”
BackgroundGenome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations
Barber, M. J., Mangravite, L. M., Hyde, C. L., Chasman, D. I., Smith, J. D., McCarty, C. A., Li, X., Wilke, R. A., Rieder, M. J., Williams, P. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009763 · Cited by 231 · cited 2×
“Furthermore, efficacy of statins for lowering LDL-C and for reducing CAD risk can vary greatly among individuals [6].”
BackgroundSelf-citationChen, C., Mireles, R. J., Campbell, S. D., Lin, J., Mills, J. B., Xu, J. J., & Smolarek, T. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002477 · Cited by 209 · cited 1×
“Simvastatin is transported by multidrug resistance gene 1 (MDR1, ABCB1) P-glycoprotein, multidrug resistance-associated protein 2 (MRP2, ABCC2), and organic anion-transporting polypeptide 1B1 [23,24].”
BackgroundSimon, J. A., Lin, F., Hulley, S. B., Blanche, P. J., Waters, D., Shiboski, S., Rotter, J. I., Nickerson, D. A., Yang, H., Saad, M., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.134 · Cited by 189 · cited 3×
“This study was designed to examine genetic and non-genetic factors affecting the response to simvastatin therapy in healthy, drug-naı̈ve patients [37].”
BackgroundMethodSelf-citationRole of P‐glycoprotein in Statin Drug Interactions
Holtzman, C. W., Wiggins, B. S., & Spinler, S. A. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.11.1601 · Cited by 185 · cited 1×
“Simvastatin is transported by multidrug resistance gene 1 (MDR1, ABCB1) P-glycoprotein, multidrug resistance-associated protein 2 (MRP2, ABCC2), and organic anion-transporting polypeptide 1B1 [23,24].”
BackgroundGnerre, C., Bl??ttler, S., Kaufmann, M. R., Looser, R., & Meyer, U. A. (2004) · Pharmacogenetics · doi:10.1097/00008571-200410000-00001 · Cited by 173 · cited 1×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundJi, Y., Hebbring, S., Zhu, H., Jenkins, G. D., Biernacka, J., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.250 · Cited by 160 · cited 2×
“Metabolomics brings powerful tools for mapping the metabolic state of individuals prior to treatment and global biochemical changes induced by drug treatment [7,8,9,10].”
BackgroundSelf-citationTagliacozzi, D., Mozzi, A. F., Casetta, B., Bertucci, P., Bernardini, S., Ilio, C. D., Urbani, A., & Federici, G. (2003) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2003.247 · Cited by 156 · cited 1×
“. The analysis was conducted using an Agilent 5975 GC/MSD. Bile acids were extracted using a sample preparation involving protein precipitation as described in Tagliacozzi et al.”
MethodKeskitalo, J., Kurkinen, K., Neuvonen, P., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.25 · Cited by 148 · cited 1×
“Polymorphisms in these proteins are known to influence simvastatin pharmacokinetics [25,26,27].”
BackgroundKaddurah-Daouk, R., Boyle, S. H., Matson, W., Sharma, S., Matson, S., Zhu, H., Bogdanov, M. B., Churchill, E., Krishnan, R. R., Rush, A. J., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.22 · Cited by 129 · cited 2×
“Metabolomics brings powerful tools for mapping the metabolic state of individuals prior to treatment and global biochemical changes induced by drug treatment [7,8,9,10].”
BackgroundSelf-citationBurkard, I., von Eckardstein, A., & Rentsch, K. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.08.016 · Cited by 125 · cited 1×
“. Analysis separations were performed by the Agilent 1200 RRLC (rapid resolution liquid chromatograph) using a Zorbax 1.8 micron column; bile acids were detected with the 4000 Qtrap (Applied Biosystems) by monitoring the analytes under multiple reaction-monitoring mode as described in Burkard et al.”
MethodInfluentialZhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 121 · cited 2×
“Furthermore, efficacy of statins for lowering LDL-C and for reducing CAD risk can vary greatly among individuals [6].”
BackgroundThe JUPITER Trial: Results, Controversies, and Implications for Prevention
Ridker, P. M. (2009) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.868299 · Cited by 114 · cited 1×
“, myopathy, increased risk for type 2 diabetes mellitus [5].”
BackgroundKaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Watkins, S. M., & Krauss, R. M. (2010) · Metabolomics · doi:10.1007/s11306-010-0207-x · Cited by 107 · cited 2×
“In our previous study we evaluated over 300 lipid species within eight lipid classes and found that baseline cholesterol ester and phospholipid metabolites correlated with LDL-C response to treatment [17].”
BackgroundSelf-citationZhao, J. J., Xie, I. H., Yang, A. Y., Roadcap, B. A., & Rogers, J. D. (2000) · Journal of Mass Spectrometry · doi:10.1002/1096-9888(200009)35:9<1133::aid-jms42>3.0.co;2-x · Cited by 82
Pharmacogenomics of statin response
Mangravite, L. M., & Krauss, R. M. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328235a5a2 · Cited by 77 · cited 1×
“Numerous studies, by members of this group and others, have identified genetic polymorphisms that contribute to variability in the LDL-C response to statins [6], but only a small proportion of the variance has been explained by these factors [11].”
BackgroundSelf-citationVeiga, P., Juste, C., Lepercq, P., Saunier, K., Béguet, F., & Gérard, P. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2004.10.042 · Cited by 74 · cited 1×
“The cholesterol to coprostanol ratio has been used as a measure of ability to remove cholesterol from circulation, and has been shown to be controlled by the amount of coprostanoligenic bacteria in the gut [19].”
MethodPhillips, K. M., Ruggio, D. M., & Bailey, J. A. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00257-1 · Cited by 74 · cited 1×
“Plasma LDL-C, HDL-C, apoAI and apoB were measured as described previously (Simon et al., 2006). Lipid extraction, solid-phase extraction, and capillary gas-liquid chromatography were used for quantitative analysis of sterols according to the method of Phillips et al.”
MethodThe expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells
Rodrigues, A. C., Curi, R., Genvigir, F. D. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.85 · Cited by 72 · cited 1×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundXiang, X., Han, Y., Neuvonen, M., Pasanen, M. K., Kalliokoski, A., Backman, J. T., Laitila, J., Neuvonen, P. J., & Niemi, M. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832bcf7b · Cited by 60 · cited 2×
“The present results are generally consistent with those published recently from a much smaller study population [16] and demonstrate that SLCO1B1 plays an important role in hepatic uptake of bile acids as well as simvastatin.”
ResultDeo, A. K., & Bandiera, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022194 · Cited by 59 · cited 1×
“Primary bile acids (CA and CDCA) and simvastatin are all metabolized by the P450 enzyme CYP3A4 [21,22].”
BackgroundPharmacogenomics of statin response.
Mangravite, L. M., Wilke, R. A., Zhang, J., & Krauss, R. M. (2008) · PubMed · Cited by 54
Self-citationChen, C., Lin, J., Smolarek, T. A., & Tremaine, L. M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015677 · Cited by 42 · cited 1×
“Polymorphisms in these proteins are known to influence simvastatin pharmacokinetics [25,26,27].”
BackgroundYamasaki, D., Nakamura, T., Okamura, N., Kokudai, M., Inui, N., Takeuchi, K., Watanabe, H., Hirai, M., Okumura, K., & Sakaeda, T. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.01.009 · Cited by 36 · cited 1×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundTazuma, S., Kajiyama, G., Mizuno, T., Yamashita, G., Miura, H., Kajihara, T., Hattori, Y., Miyake, H., Nishioka, T., Hyogo, H., et al. (1998) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199806000-00015 · Cited by 33 · cited 1×
“Interactions between simvastatin and selected bile acids competing for membrane transport may be responsible for some of the off target effects of the drug [33].”
Background
Cited by
Nakatsuji, T., Chen, T. H., Narala, S., Chun, K. A., Two, A. M., Yun, T., Shafiq, F., Kotol, P. F., Bouslimani, A., Melnik, A. V., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4680 · Cited by 1,095
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Sequencing and beyond: integrating molecular 'omics' for microbial community profiling
Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafquat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3451 · Cited by 719
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Self-citation
Metadata
- Authors
- Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Wojnoonski, K., Watkins, S. M., Trupp, M., & Krauss, R. M.
- Affiliations
- Duke Medical Center (US)
- Rosa (United States) (US)
- North Carolina State University (US)
- University of Idaho (US)
- SRI International (US)
- Corresponding author
- Kaddurah-Daouk, Rima
- Krauss, Ronald M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-13
- Volume
- 6
- Issue
- 10
- Pages
- e25482
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3192752
- OpenAlex
- W1998108632
- Cited by
- 193
- References
- 44
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 12 · 2018: 19 · 2017: 13 · 2016: 14 · 2015: 12 · 2014: 8 · 2013: 17 · 2012: 9
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-05-06)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Washington
- National Heart, Lung, and Blood Institute (U01HL069757)
- National Institute of General Medical Sciences (GM078233, R24GM078233)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- simvastatin, LDL cholesterol lowering, gut microbiota metabolites, secondary bile acids, cholesterol biosynthesis, bile acid transporters, SLCO1B1, rs4149056, pharmacogenetics, metabolomics, personalized treatment, cardiovascular disease
- MeSH terms
- Bile Acids and Salts, Demography, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Models, Biological, Pharmacogenetics, Treatment Outcome, Simvastatin, Polymorphism, Single Nucleotide, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, Gastrointestinal Tract, Metagenome, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.